BIOMAT Database Logo BIOMAT Database Logo

Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. 1999

D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Department of Psychiatry, Case Western Reserve University Medical School, Cleveland, OH 44106, USA.

In this study, we demonstrate that clozapine and other atypical antipsychotic drugs induce a paradoxical internalization of 5-hydroxytryptamine-2A receptors in vitro and a redistribution of 5-hydroxytryptamine-2A receptors in vivo. We discovered that clozapine, olanzapine, risperidone and the putative atypical antipsychotic drug MDL 100,907 all induced 5-hydroxytryptamine-2A receptor internalization in fibroblasts stably expressing the 5-hydroxytryptamine-2A receptor in vitro. Two 5-hydroxytryptamine-2A antagonists (mianserin and ritanserin), which have been demonstrated to reduce negative symptoms in schizophrenia, also caused 5-hydroxytryptamine-2A receptor internalization. Four different drugs, each devoid of 5-hydroxytryptamine-2A antagonist activity, had no effect on the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro. Treatment of rats for seven days with clozapine induced an increase in intracellular 5-hydroxytryptamine-2A receptor-like immunoreactivity in pyramidal neurons, while causing a decrease in labeling of apical dendrites in the medial prefrontal cortex. This redistribution of 5-hydroxytryptamine-2A receptors in pyramidal neurons was also seen when rats were chronically treated with another atypical antipsychotic drug, olanzapine. The typical antipsychotic drug haloperidol, however, did not induce a redistribution of 5-hydroxytryptamine-2A receptors in pyramidal neurons in the medial prefrontal cortex. Taken together, these results demonstrate that several atypical antipsychotic drugs with high 5-hydroxytryptamine-2A receptor affinities induce a redistribution of 5-hydroxytryptamine-2A receptors both in vivo and in vitro. It is conceivable that the loss of 5-hydroxytryptamine-2A receptors from the apical dendrites of pyramidal neurons is important for the beneficial effects of atypical antipsychotic drugs and other 5-hydroxytryptamine-2A antagonists in schizophrenia.

UI MeSH Term Description Entries
D008803 Mianserin A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. Lerivon,Mianserin Hydrochloride,Mianserin Monohydrochloride,Org GB 94,Tolvon,Hydrochloride, Mianserin,Monohydrochloride, Mianserin
D010880 Piperidines A family of hexahydropyridines.
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003712 Dendrites Extensions of the nerve cell body. They are short and branched and receive stimuli from other NEURONS. Dendrite
D005464 Fluorobenzenes Derivatives of BENZENE that contain FLUORINE. Fluorobenzene
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol

Related Publications

D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
N-methyl-D-aspartate (NMDA) receptors in the ventral tegmental area: subcellular distribution and colocalization with 5-hydroxytryptamine(2A) receptors.
April 2000, Journal of neuroscience research,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists.
January 1991, Scandinavian journal of gastroenterology. Supplement,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.
April 2013, Expert opinion on investigational drugs,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
August 2010, Journal of medicinal chemistry,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
The interaction of WB4101, and other alpha-adrenoceptor antagonists, on 5-hydroxytryptamine receptors.
May 1979, The Journal of pharmacy and pharmacology,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Subcellular distribution of reserpine and 5-hydroxytryptamine in blood platelets after treatment with reserpine in vitro and in vivo.
January 1974, Biochemical pharmacology,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Subcellular distribution of 5-hydroxytryptamine in the rabbit brain.
December 1962, The Japanese journal of physiology,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Subcellular distribution of 5 hydroxytryptamine in pig platelets.
April 1971, Biochemical pharmacology,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain.
July 2000, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
D L Willins, and S A Berry, and L Alsayegh, and J R Backstrom, and E Sanders-Bush, and L Friedman, and B L Roth
Subcellular distribution and chemical nature of the receptor for 5-hydroxytryptamine in the central nervous system.
August 1969, Journal of neurochemistry,
Copied contents to your clipboard!